FIRST trial
GSK’s Zejula-Jemperli Combination Achieves Primary Endpoint in Ovarian Cancer Trial, Falls Short on Overall Survival
GSK, Zejula, Jemperli, ovarian cancer, FIRST trial, progression-free survival, overall survival
Actionable Insights Powered by AI
GSK, Zejula, Jemperli, ovarian cancer, FIRST trial, progression-free survival, overall survival